MarketCap
Facebook
X
Telegram
AlloVir Revenue | ALVR
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue AlloVir
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | 165 K | 1.14 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.14 M | 165 K | 650 K |
Quarterly Revenue AlloVir
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 165 K | 165 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 165 K | 165 K | 165 K |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Biotechnology industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AbbVie
ABBV
|
16.6 B | $ 263.04 | 0.49 % | $ 465 B |  USA |
 |
AbCellera Biologics
ABCL
|
75.1 M | $ 11.41 | 2.15 % | $ 3.41 B |  Canada |
 |
Фармсинтез
LIFE
|
372 M | - | - | - |  Russia |
 |
Aclaris Therapeutics
ACRS
|
7.83 M | $ 5.53 | 6.02 % | $ 678 M | USA |
 |
ADC Therapeutics SA
ADCT
|
81.4 M | $ 1.09 | 3.74 % | $ 139 M |  Schweiz |
 |
Amryt Pharma plc
AMYT
|
223 M | - | - | $ 621 M |  Britain |
 |
Clovis Oncology
CLVS
|
36 M | - | -7.23 % | $ 13 M | USA |
 |
Chimerix
CMRX
|
212 K | - | - | $ 756 M | USA |
 |
Concert Pharmaceuticals
CNCE
|
32.6 M | - | - | $ 401 M | USA |
 |
ADMA Biologics
ADMA
|
510 M | $ 8.61 | 0.16 % | $ 2.05 B | USA |
 |
Eiger BioPharmaceuticals
EIGR
|
15.8 M | - | -9.21 % | $ 2.55 M | USA |
 |
Fusion Pharmaceuticals
FUSN
|
2.07 M | - | - | $ 1.41 B | Canada |
 |
Guardion Health Sciences
GHSI
|
12.2 M | - | -0.31 % | $ 3.64 M | USA |
 |
Genocea Biosciences
GNCA
|
1.64 M | - | -15.0 % | $ 3.04 M | USA |
 |
Gritstone Oncology
GRTS
|
16.3 M | - | 0.42 % | $ 213 M | USA |
 |
G1 Therapeutics
GTHX
|
82.5 M | - | - | $ 370 M | USA |
 |
Harpoon Therapeutics
HARP
|
31.9 M | - | - | $ 763 M | USA |
 |
Humanigen
HGEN
|
2.51 M | - | -81.12 % | $ 4.28 M | USA |
 |
HOOKIPA Pharma
HOOK
|
43.9 M | - | -6.92 % | $ 79.4 M | USA |
 |
Intercept Pharmaceuticals
ICPT
|
77.2 M | - | - | $ 643 M | USA |
 |
IMV
IMV
|
188 K | - | - | $ 13.1 M | Canada |
 |
Intra-Cellular Therapies
ITCI
|
199 M | - | - | $ 13.6 B | USA |
 |
Chinook Therapeutics
KDNY
|
6.13 M | - | - | $ 2.6 B | USA |
 |
Kaleido Biosciences
KLDO
|
1.1 M | - | -3.69 % | $ 12.4 M | USA |
 |
Kronos Bio
KRON
|
9.85 M | - | 1.49 % | $ 50.8 M | USA |
 |
Karuna Therapeutics
KRTX
|
654 K | - | - | $ 12.2 B | USA |
 |
Landos Biopharma
LABP
|
18 M | - | 0.58 % | $ 144 M | USA |
 |
La Jolla Pharmaceutical Company
LJPC
|
75.7 M | - | - | $ 154 M | USA |
 |
LogicBio Therapeutics
LOGC
|
5.41 M | - | - | $ 229 M | USA |
 |
Lumos Pharma
LUMO
|
2.05 M | - | - | $ 35.3 M | USA |
 |
Merrimack Pharmaceuticals
MACK
|
144 M | - | - | $ 216 M | USA |
 |
Stealth BioTherapeutics Corp
MITO
|
21.1 M | - | - | $ 23.9 M | USA |
 |
Mirati Therapeutics
MRTX
|
12.4 M | - | - | $ 3.3 B | USA |
 |
9 Meters Biopharma
NMTR
|
1.88 M | - | -42.97 % | $ 1.05 M | USA |
 |
Nymox Pharmaceutical Corporation
NYMX
|
5 K | - | -19.68 % | $ 18.4 M | Canada |
 |
Oncternal Therapeutics
ONCT
|
785 K | - | -24.12 % | $ 1.56 M | USA |
 |
Opiant Pharmaceuticals
OPNT
|
47.8 M | - | - | $ 109 M | USA |
 |
Orchard Therapeutics plc
ORTX
|
22.7 M | - | 1.02 % | $ 90.8 M | Britain |